4055-39-4

Usage

Uses

Used in Pharmaceutical Industry:
Mitomycin A is used as an antitumor agent for its ability to inhibit tumor growth and progression. It is particularly effective against various types of cancer, including solid malignancies.
Used in Cancer Treatment:
Mitomycin A is used as a chemotherapy agent for its potent antitumor activity. It is often administered in combination with other chemotherapeutic drugs to enhance the overall treatment efficacy and overcome drug resistance in cancer patients.
Used in Research and Development:
Due to its unique chemical properties and high toxicity, Mitomycin A is also utilized in research and development for the study of its mechanism of action, potential applications, and the development of less toxic or more targeted therapies based on its structure and function.

Upstream product

• 67-56-1 methanol 
• 122644-74-0 1a-acetyl-7-demethoxy-6,7-dihydro-7,7-(ethylenedioxy)-6-(phenylselenyl)mitomycin A 
• 7041-61-4 7-hydroxy-9a-methoxymitosane 
• 20667-76-9 1-methyl-3-(p-tolyl)triaz-1-ene 
• 50-07-7 mitomycin C 
• 132732-87-7 (8aR)-8a-bromoalbomitomycin A 
• 20667-76-9 3-methyl-1-p-tolyltriazene 
• 132732-87-7 (8aS)-8a-bromoalbomitomycin A 
• 124-41-4 sodium methylate 
• 128583-70-0 7-O-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-9a-methoxymitosane 
• 186581-53-3 diazomethane 

Downstream Products

• 122-80-5 N-acetyl-p-phenylenediamine 
• 36717-77-8 (2-(2-nitro-1H-imidazol-1-yl)ethan-1-amine) 
• 2706-56-1 2-(aminoethyl)pyridine 
• 106-49-0 p-toluidine 
• 134136-38-2 7-N-<4-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)phenyl>-9a-methoxymitosane 
• 78327-27-2 C₁₈H₁₉N₅O₅S 
• 88854-60-8 C₂₀H₂₃N₅O₅S 
• 88854-59-5 C₂₀H₂₂N₆O₅ 
• 134757-48-5 C₂₃H₂₃N₅O₅ 
• 88854-56-2 C₂₂H₂₄N₆O₆ 
• 134757-47-4 C₂₁H₂₁N₅O₈ 
• 84397-45-5 C₁₈H₂₀N₆O₅ 
• 118598-93-9 C₂₃H₂₅N₃O₆S 
• 88854-46-0 C₂₂H₂₄N₄O₆ 

Relevant academic research and scientific papers

7-(diphenylmethyl)oxy-9a-methoxymitosane

7-(Diphenylmethyl)oxy-9a-methoxymitosane is a novel intermediate for conversion into 7-amino and 7-oxy-9a-methoxymitosanes and is also useful for inhibiting mammalian tumor growth. The compound is prepared by reacting 7-hydroxy-9a-methoxymitosane with diazodiphenylmethane. In a preferred reaction, the compound is prepared from mitomycin C via 7-hydroxy-9a-methoxymitosane without drying (water removal). The intermediate is advantageously converted to the very effective anti-tumor agent 7-[2-(4-nitrophenyldithio)ethylamino]-9a-methoxymitosane in unexpectedly high yields using a two step process where the first step constitutes conversion to 7-[2-(2-pyridyldithio)ethylamino]-9a-methoxymitosane or 7-[2-(3-nitro-2-pyridyldithio)ethylamino]-9a-methoxymitosane.

First preparation of mitomycins specifically labeled with deuterium at the C6-methyl position

The C6-methyl group of mitomycins was specifically labeled with deuterium. 7,7-(Ethylenedioxy)mitomycin (8), a masked quinonoid compound derived from mitomycin A (2), played an important role in this methodology.

Mitomycins and processes for their preparation

Mytomycin derivatives of formula [wherein W represents deuterium (2H) or tritium (3H);, X represents a methoxy or amino group; one of R1 and R2 represents a carbamoyloxymethyl group and the other represents a hydrogen atom; or optionally R1 and R2 are combined together and represent a methylene group (=CH2), Y represents a hydrogen atom or a methyl group; and, Z represents hydrogen, a methyl group or an acyl group] are of interest for metabolic studies. The compounds may be prepared from novel 6-methylenemitomycins (the latter derived from novel 6-phenylselenomitomycins) by reduction with labelled borohydride.

1a-7-substituted derivatives of mitomycin and uses thereof

This invention discloses 1a- and 7-substituted derivatives of mitosanes containing thiocarbamoyl and glycosyl residues. The compounds possess antibacterial and antitumor activity, with a concomitant reduction in bone marrow toxicity as compared to the parent compounds.

Preparation and Antitumor Activity of New Mitomycin A Analogues

A series of 26 mitomycin A analogues including 23 new ones was prepared by a variety of methods.The most useful methods were alkoxide exchange on mitomycin A and treatment of 7-hydroxymitosane with 3-substituted 1-phenyltriazenes.Many of the new analogues were superior to mitomycin C in the P388 leukemia assay and the more stringent subcutaneous B16 melanoma assay both in mice.Four of them gave long-term survivors in the latter assay.Quantitative correlations between log P and antitumor activity were not possible, but some guidelines for future analogue development are proposed.